The PCSK9 Story: Advances in Cholesterol Metabolism, Cardiovascular Complications and Beyond

Dear Colleagues,

Since our first identification in 2003 of PCSK9 and its natural mutations causing familial hypercholesterolemia and its relationship to cardiovascular complications, a huge field of research on PCSK9 has emerged leading to clinical prescriptions of a new class of lipid lowering drugs. Anti-PCSK9 antibodies are now very efficient in fighting hypercholesterolemia and cardiovascular diseases. The PCSK9 story is an amazing example of successful translational research that revolutionized the field of LDL-cholesterol. However, many aspects of the PCSK9 biology still need to be elucidated, which may lead to new and exciting applications.

This Special Issue of Metabolites, “The PCSK9 Story: Advances in Cholesterol Metabolism, Cardiovascular Complications, and Beyond” will be dedicated to PCSK9 and to anti-PCSK9 therapies, notably antibodies and siRNA, in cholesterol and cardiovascular diseases.

This issue will include PCSK9 hepatic but also extrahepatic functions and their implications in atherosclerosis through LDL-cholesterol homeostasis or beyond. Additionally, it will cover the role of PCSK9 in cancer, inflammation, infectious, and neurological diseases. It will provide new insights into genetics, molecular, biochemical, cellular, animal, pharmacological, and clinical studies from fundamental and applied research angles, as well as the various roles of PCSK9, the measurement of its various forms, and its modulation by nutritional or therapeutic approaches.

Dr. Marianne Abifadel
Prof. Dr. Catherine Boileau
Dr. Nabil G. Seidah
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.